

In the Specification

Please replace the paragraph at page 8, lines 17 through 25 with the following paragraph:

B¹

The invention also embodies monoclonal antibodies or antigen binding fragments thereof which have binding specificity for ouabain and do not cross react with digoxin, expressed by or derived from cell lines deposited with the A.T.C.C., 10801 University Boulevard, Manassass, VA, 02110-2209, on October 1, 1999, designated ATCC. Nos. PA-812, PA-813, PA-814 and PA-815. The cell lines which express the anti-ouabain monoclonal antibody deposited with the ATCC are designated as B cell hybridomas from spleen cells of A/J mice which express (produce) the anti-ouabain monoclonal antibody (e.g., 1-10 α oua mAb, 7-1 α oua mAb, 5A12 α oua mAb and 8E4 α oua mAb) of the IgG1, κ or IgG2b, κ isotype.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

In the Claims

Please amend Claims 1, 2, 5, 6 and 38. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i-ii).

- B²
1. (Amended) A monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by about 100 μ M of digoxin.
 2. (Amended) The monoclonal antibody of Claim 1 selected from the group consisting of: 1-10 (A.T.C.C. Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813), 8E4 (A.T.C.C. Accession number PTA-815) and an antigen binding fragment thereof.
 5. (Amended) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as a monoclonal antibody selected from the group consisting of: 1-10 (Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813), 8E4
- B³